A British startup called Potential Sciences launched on November 5, 2026, with a plan to use AI trained on computer-generated biochemical data to accelerate drug discovery — bypassing much of the laboratory experimentation that makes the process slow and costly.
The company, backed by SovAI — the UK government’s AI venture capital fund — and Twin Path Ventures, has raised seed funding in the tens of millions of dollars. Founders declined to disclose the exact figure or valuation.
Potential Sciences intends to build large-scale chemical datasets by using physics-based simulations of atomic interactions, scaling up through small molecules to complex amino acids and proteins. Those datasets would then be used to train AI models capable of predicting how drug candidates interact with disease-related proteins, potentially identifying viable compounds without requiring repeated physical lab trials.
“We want molecules that are never going to work in the clinic to fail fast,” said founder and CEO Hatem Helal. “That means having better predictors of how they will behave as they interact with human biology.”
Helal said the approach could also make it economical for pharmaceutical companies to develop drugs for rare conditions that have previously gone untreated, and could eventually support treatments tailored to individual patients’ biology.
Experts are cautiously measured about the prospects. Peter Wolynes, a chemistry professor at Rice University, said the approach would likely represent an improvement over current methods, but noted that protein engineering remains at an early stage. “The engineering is at the level of the Romans, not of the Renaissance,” he told WIRED.
The startup enters a field where figures such as Demis Hassabis — who won the Nobel Prize for Chemistry for his work at Google DeepMind — have argued that AI could eventually produce major scientific breakthroughs. Whether drug discovery will be among the first fields transformed by that shift remains to be seen.
Source: WIRED